How Long Does It Take For Peptide Therapy To Work?

If you are on a GLP-1 medication, appetite changes usually show up in the first 3 to 5 weeks and measurable weight loss by week 12. If you are on tesamorelin, the trials measured visceral fat at 26 weeks. If you are on BPC-157, CJC-1295 or ipamorelin, the honest answer is that nobody can tell you, because the human studies that would produce a timeline have not been done.

That gap is the part most peptide timelines leave out. This page sorts the answer by how much human evidence sits behind it, so you know which numbers you can plan around and which ones are guesses.

Key takeaways

• Timelines are only as reliable as the trials behind them, and those vary enormously between peptides.
• GLP-1 medications have the clearest week-by-week data in this category, from trials with over 2,500 participants.
• Tesamorelin and bremelanotide are FDA approved and have dated trial endpoints, but only for specific populations.
• Sermorelin rests on 1 small study from 1997, and the effect faded by week 16.
• BPC-157, ipamorelin, TB-500 and thymosin alpha-1 have no human timeline data for the uses they are marketed for.
• As of September 2026, none of the unapproved peptides here can be lawfully compounded in the US, despite widespread reporting to the contrary.

The short answer, and why it is not 1 number

“Peptide therapy” covers 3 groups of drugs that behave nothing alike.

The first group is FDA approved, tested in large trials, and has published timelines you can plan around. The second has small or old human studies that point in a direction without settling it. The third has essentially no human evidence, and every timeline quoted for it traces back to rodent work or to marketing copy.

A clinic that quotes you “4 to 6 weeks” without saying which group your peptide falls into is giving you an average across all 3. That number is not wrong so much as meaningless.

If you want the per-peptide view rather than the evidence-quality view, our peptide therapy results timeline covers the same ground organised by peptide type.

Group 1: Peptides with FDA approval and dated trial endpoints

GLP-1 medications: semaglutide and tirzepatide

These have the strongest timeline data of anything in the category.

Semaglutide (Wegovy). The dose climbs over roughly 16 weeks, from 0.25 mg to the 2.4 mg maintenance dose that begins in week 17. Steady state in the blood arrives after 4 to 5 weeks of weekly dosing.

What the trials measured:

Timepoint	What happened
Weeks 4 to 5	Drug reaches steady state in the blood
Week 12	Daily calorie intake down 24% against placebo, at a sub-maximal 1.0 mg dose
Week 20	Calorie intake down 35%; average weight loss 10.6% in the STEP 4 run-in
Week 68	Average loss 14.9% against 2.4% on placebo. 69% of participants lost at least 10%. This is the trial’s final timepoint and its maximum

Tirzepatide (Zepbound). The dose climbs over about 20 weeks to reach 15 mg.

Timepoint	What happened
Week 3	Calorie intake down 525 per day against placebo, at the 5 mg starting dose. Average loss 3.7 kg
Week 6	Average loss 7.0 kg
Week 12	82% had already lost at least 5%, among 1,545 participants who took at least 75% of their doses
Weeks 24 to 36	Most people reach their plateau, later at higher starting BMI
Week 72	Average loss 15.0% at 5 mg, 19.5% at 10 mg, 20.9% at 15 mg, against 3.1% on placebo

Two caveats worth knowing before you set expectations against those figures.

Trial numbers are not what most people get. A study of 18,386 matched patients found real-world semaglutide loss of 8.3% at 12 months, roughly half the trial result. Read that comparison carefully: those patients were on the diabetes-labelled product, which caps at 2 mg, not the 2.4 mg weight-management dose the trials used. Add to that more than half of patients stopping treatment, and a different mix of health conditions.

Appetite suppression does not hold steady. A 2026 trial found the subjective sense of reduced appetite was significant at week 20 but not at weeks 40 or 60, even though measured calorie reduction persisted. If the effect feels weaker at month 10 than it did at month 5, that is documented, not imagined.

What happens if you stop. In the STEP 1 extension, participants who stopped semaglutide regained about two thirds of their loss over the following 52 weeks, ending at 5.6% below where they started rather than 17.3%. In SURMOUNT-4, people switched to placebo after 36 weeks gained 14.0% while those who stayed on tirzepatide lost a further 5.5%. A 2026 review of 48 studies put average regain at 60% of lost weight 1 year after stopping.

Side effect timing. Nausea, diarrhoea, vomiting and constipation cluster in the days after each dose increase, which is why they are concentrated across the 16 to 20 week titration window. About 98% of these events are mild to moderate, and both labels allow holding the current dose an extra 4 weeks if you are struggling. Fewer than 5% of trial participants stopped treatment because of them.

Tesamorelin

FDA approved, for 1 specific use, worded on the label as reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It does not treat the lipodystrophy itself.

Across 2 trials totalling 816 participants, visceral fat fell 14% to 18% at week 26, and IGF-1 rose by about 107 ng/mL over the same period. Body weight and waist circumference stayed roughly flat, so this acts on the visceral compartment rather than producing overall weight loss. Those figures come from the FDA prescribing information.

Week 26 is the endpoint the approval rests on. If you see tesamorelin marketed for general body recomposition in healthy adults, that use sits outside everything the trials measured.

Bremelanotide (PT-141)

FDA approved in 2019, for premenopausal women with acquired, generalised hypoactive sexual desire disorder. The label states plainly that it is not indicated for postmenopausal women, not for men, and not for enhancing sexual performance.

The dosing instruction is to inject at least 45 minutes before anticipated activity, which lines up with peak blood levels at about 1 hour. Worth being precise here: 45 minutes is a dosing instruction derived from pharmacokinetics, not a measured onset of effect. No trial timed how long desire takes to change.

Effect size across 2 trials of roughly 1,250 women each was statistically clear and modest, with desire scores improving 0.5 to 0.6 points against 0.2 on placebo. Nausea, flushing and headache each affected at least 10% of participants. If this is the area you are asking about, our sexual health clinic in Weston is the place to start.

Group 2: Peptides with limited human data

Sermorelin

The study everyone cites is from 1997: 19 adults aged 55 to 71, nightly injections, 16 weeks. Worth being precise about what it tested, because the drug was a norleucine-substituted GHRH analog closely related to sermorelin, not sermorelin itself. The findings are indicative rather than a direct read on the product you would be prescribed.

IGF-1 rose within 2 weeks and stayed up through week 12. Then it drifted back toward baseline by week 16, while participants were still taking it. Lean body mass increased in men only. Skin thickness increased in both sexes. Fat mass, body weight and bone density did not change.

That week 16 fade is the most useful finding in the study and the one least likely to appear in marketing material. It suggests the body adapts, which matters if you are being quoted an open-ended course of treatment.

One small, single-blind study of a related compound from nearly 30 years ago is a thin base for a timeline. Treat any sermorelin schedule as provisional.

CJC-1295

There are 2 versions of this, and almost every timeline quoted online belongs to the one most clinics do not dispense.

CJC-1295 with DAC has real pharmacology data. A single injection raised growth hormone 2 to 10 fold for at least 6 days and IGF-1 by 1.5 to 3 fold for 9 to 11 days, with a half-life of 5.8 to 8.1 days.

CJC-1295 without DAC, also sold as mod-GRF 1-29, has no peer-reviewed human studies. Its half-life is roughly 30 minutes, not 8 days.

If a clinic quotes the multi-day IGF-1 elevation while dispensing the non-DAC version, the number does not apply to what you are being given. Ask which one you are on.

Also worth stating: even for the DAC version, no human study has ever measured body composition. Muscle and fat claims for this peptide have no human trial behind them, in either version.

GHK-Cu

Small studies have reported changes in skin thickness and density after about 12 weeks of twice-daily topical use. The studies are small, largely industry-associated, and have not been replicated to modern standards. Twelve weeks is a reasonable window to judge it by, with the evidence caveat attached.

Group 3: Peptides with no human timeline

BPC-157

FDA assessed the evidence in a briefing document dated May 2026, presented to its advisory committee that July. It identified 5 human studies, 81 participants in total, none running longer than 2 weeks. Those studies used rectal, intra-articular, intravesical and intravenous administration.

FDA’s finding, in its own terms: no human pharmacokinetic data exist for BPC-157 given orally, subcutaneously, nasally or transdermally. Those are the 4 routes clinics actually sell. Nobody has published what the drug does in the body when taken the way it is dispensed. The full briefing document is public if you want to read it.

The single musculoskeletal study, 17 people with knee pain, gave thymosin beta-4 at the same time, so nothing in the result can be attributed to BPC-157 alone.

Of 36 orthopaedic studies identified in a systematic review, 35 were in rodents or cell cultures, most from 1 research group. Any “heals in 2 to 4 weeks” figure you see for BPC-157 comes from that animal work.

BPC-157 is also banned by WADA at all times, in and out of competition.

Ipamorelin

Growth hormone peaks 40 to 60 minutes after a dose. Beyond that, there are 3 human studies in the literature, 1 of which is a randomised trial, and that trial studied bowel function after surgery rather than muscle, fat or recovery.

No human study has measured IGF-1 outcomes or body composition for ipamorelin. No trial of the CJC-1295 and ipamorelin combination exists in humans at all, despite it being the most commonly sold pairing in the category.

TB-500 and thymosin alpha-1

Reviewing these in 2026, FDA found no human clinical studies evaluating TB-500 for the use it was nominated for.

There is genuine trial data on full-length thymosin beta-4 as an eye drop for dry eye and corneal disease. TB-500 is a fragment of that molecule, injected systemically. The eye drop evidence does not transfer.

Thymosin alpha-1 has the largest trial of anything in this group, and it failed. A 2025 trial published in the BMJ of 1,106 patients with sepsis found 28-day mortality of 23.4% on the drug against 24.1% on placebo, a difference that was not statistically significant. A 2025 meta-analysis found an apparent benefit overall that disappeared when the analysis was restricted to high-quality or multi-centre trials.

What actually changes your timeline

Within any given peptide, 5 things move the number:

1. Dose escalation schedule. On GLP-1s, most of the first 16 to 20 weeks is spent climbing to the dose that produces the trial results. Pausing an escalation step for tolerance adds 4 weeks.
2. Which endpoint you are watching. Blood markers move first, how you feel comes next, and body composition is last. Tesamorelin shifts IGF-1 within 2 weeks and visceral fat at 26.
3. Adherence. In the real-world semaglutide data, over half of patients stopped during follow-up, which is the largest single driver of the gap between trial and real-world results.
4. What you are measuring against. Weight fluctuates daily. Trials measure at fixed intervals against a baseline for a reason.
5. Whether the peptide has a documented mechanism for your goal. No amount of patience produces a result that has never been demonstrated in humans.

Where US law stands, September 2026

This changed recently and has been widely misreported, so it is worth separating what happened from what it means.

What happened. On 15 April 2026, FDA removed 12 peptides from its Category 2 list, the list of substances judged to present significant safety risks. BPC-157, TB-500 and injectable GHK-Cu were among them. In July 2026, an FDA advisory committee reviewed 7 peptides and voted favourably on 6, against the recommendation of FDA’s own staff.

What it does not mean. Neither step made anything legal to compound. Coming off Category 2 removes an objection; it does not create eligibility. Advisory committee votes are not binding. For any of this to change, FDA has to publish a proposed rule, take public comment, and issue a final rule. No proposed rule has been published, and no deadline requires one. The last comparable process ran 26 months.

Which peptides this covers. Only BPC-157 and TB-500 of the peptides discussed on this page were part of the July review, alongside KPV, MOTS-c, Semax, Epitalon and DSIP. CJC-1295, ipamorelin and thymosin alpha-1 were not reviewed at all, and nothing about their status changed in 2026. Ipamorelin in fact remains on the Category 2 list, which is a worse regulatory position than the peptides that came off it, not the same one.

So as of September 2026, none of BPC-157, CJC-1295, ipamorelin, TB-500 or thymosin alpha-1 can be lawfully compounded in the US, and FDA can still act against pharmacies producing them.

If a provider offers you a compounded peptide, ask what legal basis they are compounding it under. It is a fair question and a good test of who you are dealing with.

When to say it is not working

Useful checkpoints, assuming you are on something with real evidence behind it:

• Week 4 on a GLP-1: you should notice some appetite change. If nothing has shifted, raise it, because dose timing and injection technique are worth checking.
• Week 12: most people have lost at least 5%. If you have not, you are not a failure case. In the tirzepatide trials, 70% of people who had lost under 5% at week 12 got there by week 24.
• Week 20 to 24: you should be at or near your maintenance dose and seeing a clear trend. If not, this is the point to reassess rather than wait.
• Week 26 on tesamorelin: this is the trial endpoint. If imaging shows no change, the conversation should change.
• Week 16 on sermorelin: the one study available showed the effect fading here. Worth reviewing rather than continuing on autopilot.

Bring your own record. Weekly weights, a note on appetite and energy, and any side effects and when they appeared, will tell your provider more than recall will.

Talk to us in Weston

If you are considering peptide therapy or you are already on something and unsure whether it is working, we will go through what the evidence supports for your situation, what it does not, and what a realistic timeline looks like. That includes telling you when a peptide you have read about does not have the evidence behind it to justify starting.

Book a consultation at our wellness health center in Weston, FL, and read more about the team who would be looking after you.

Disclaimer: This content is for informational purposes only and is not medical advice. Peptide therapy should only be undertaken under the supervision of a licensed healthcare provider. Individual results vary.

FAQs

How long before I notice anything on peptide therapy?

It depends entirely on which peptide. On a GLP-1, appetite changes typically appear in the first 3 to 5 weeks. On tesamorelin, the trial endpoint is 26 weeks. For BPC-157, ipamorelin and TB-500, no human study has established a timeline for the uses they are marketed for.

Why do most sites say 4 to 6 weeks?

It is an average across peptides with very different evidence behind them. Applied to a specific peptide it is usually not traceable to any trial.

If I have seen nothing by week 12, should I stop?

Not automatically. In the tirzepatide trials, 70% of people who had lost under 5% at week 12 reached that mark by week 24, taking about 25 weeks on average. Week 12 is a point to review dose and adherence with your provider, not to quit.

Do results last after I stop?

For GLP-1s, mostly not. Around 60% of lost weight returns within a year of stopping, and a 2026 model projects about 75% over the longer term, settling below starting weight rather than back at it. This is why maintenance planning is part of the conversation from the start.

Is it true peptides became legal in 2026?

No. FDA removed 12 peptides from a restricted list in April 2026, and in July 2026 an advisory committee voted favourably on 6 of 7 it reviewed. Neither step permits compounding, and no rule has been issued since. Two points usually get lost in the coverage: the July review covered BPC-157 and TB-500 but not CJC-1295, ipamorelin or thymosin alpha-1, and ipamorelin is still on the restricted list. As of September 2026 none of these can be lawfully compounded in the US.

Which peptides have real human evidence?

Tesamorelin and bremelanotide are FDA approved with published trial endpoints, each for a specific population. GLP-1 medications have the largest trials in the category. Sermorelin and CJC-1295 with DAC have limited human data. BPC-157, ipamorelin, TB-500 and thymosin alpha-1 do not have human timeline evidence for their marketed uses.